CNS SALES

Discussion in 'AstraZeneca' started by Anonymous, Jul 31, 2014 at 11:14 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Jealous and not sure of your future. We are the best sales team at AZ. XR was not launched in 97 fool. We are here to take over!!!!
     

  2. Anonymous

    Anonymous Guest

    with all due respect XR grew to well over $1 billion and is still over 1 billion in sales. done with a fickle group of specialists who like to make up their own rules when treating mental illness, in a very crowded market (generics also) with very limited manage care access. i dont care what anyone thinks, IMO it definitely takes some selling ability to pull that off..
     
  3. Anonymous

    Anonymous Guest

    Think what you want but cns is here to stay. We will be selling the constipation drug, Now laugh if you want but what else is out there to launch. So we will be here for awhile...security.
     
  4. Anonymous

    Anonymous Guest

    XR is no different than Seroquel. In fact it's probably worse. I've sold both and it's an old drug and the generic works as well.
     
  5. Anonymous

    Anonymous Guest

    It takes no selling ability. You lost the ability to make an impact years ago. It's just habit for the docs. They have XR samples. Generic Seroquel works just as well. Quit patting yourselves on the back. The time to sell Seroquel was at launch and for the next five years competing with Risperdal and Zyprexa. All you numb nuts are doing is riding the coattails of those who came before you. How pathetic.
     
  6. Anonymous

    Anonymous Guest

    It does not matter, we have gone into insane asylums, mental wards, and mental Heath centers.
    We are in the battleground! We have proven ourselves year after year. We are the premier sales team.
     
  7. Anonymous

    Anonymous Guest

    Sold that drug at one time. When XR was launched AstraZeneca went on a campaign to differentiate XR from IR by saying its receptor affinities made it a better drug for the patient than generic IR. I was always surprised that we got away with that from the FDA. XR was an extended version of IR, pure and simple. I wonder if AZ tries to differentiate it that way still?

    Naturally the other thing we told physicians was that they couldn't use IR for a patient with the newer indications as only XR was approved and there was no data on IR, or the dosing would be different. True enough, but of course the newer indications came out just prior to the generic hitting the market and we weren't incentivized on the older formulation. In many cases IR was still growing and would soon be much less expensive to the patient. In essence we were selling against ourselves and trying to get switches from IR to XR, or position the drug as a better choice than Abilify for bipolar depression.
     
  8. Anonymous

    Anonymous Guest

    Not true. The competitive environment has changed dramatically since then and yet XR is still selling billions. Treating mental illness is much more difficult to diagnose/treat then say COPD. Not really any physical diagnostic tools to determine MDD from BPD (compared to say a spirometer for COPD). it takes a bit more clinical knowledge and know how to promote this product. You sound like you've never sold XR, in which case your credibility is nill.
     
  9. Anonymous

    Anonymous Guest

    I sold Seroquel and then XR for 13 years and have sold antidepressants and mood stabilizers too. We reps that launched Seroquel opened up off label markets for PTSD and other anxiety disorders, child psychiatry, sundowning, and even put it in chicken feed to fatten them up. So you can quit feeling special about your special clinical knowledge. Try using that to find a job elsewhere smarty pants.

    We also worked to get Seroquel on formularies and influenced thought leaders to promote the drug that you feel so special about promoting. That was the challenge, to turn a product that was only supposed to be worth $300 million into a $6 billion dollar a year product. You are just squeezing the last blood out of that turnip.

    XR is selling because you sample it but the majority of quetiapine sales are generic. So much for your superiority. You sell an old has been.
     
  10. Anonymous

    Anonymous Guest

    Curious as to how the challenger model worked for CNS. My DSM is talking about bringing it to our district. Personally, I think it is an inappropriate model for our type of sales but would like to hear from those who have been using it. (Or at least faking it)
     
  11. Anonymous

    Anonymous Guest

    X100
     
  12. Anonymous

    Anonymous Guest

    True. He's totally untrustworthy. Always looking out for himself
     
  13. Anonymous

    Anonymous Guest

    What a crock of total shit! Challenger Model our ass! My call, when I can get in, is "Sign here doc". Nobody challenges the doc to do a damn thing! XR has been a joke from day one. Most docs see it as a patent ploy when IR went generic. Challenger Model… yeah right!
     
  14. Anonymous

    Anonymous Guest

    The Challenger Sale is old Lilly training program from 20 years ago ha ha. You see where that has got them. There is no creativity or passion left in pharma. it is a robot sale completely
    w/ canned approved legal I pad detail. No more connector value or relationship building taking place which is why it attracts 25-35 yo who are just trying to get a leg up in the world to payback their student loans @ 6%, buy a house, have a baby & live the American dream which by the way is meh. Oldies need to face the facts... If u do not have some of your $ tucked away then move into real estate or direct marketing.